NRX Pharmaceuticals (NRXP) Net Cash Flow (2017 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Net Cash Flow of -$1.1 million for Q1 2026, down 126.53% year-over-year from $4.1 million in Q1 2025, and down 274.24% quarter-over-quarter from $625000.0 in Q4 2025.
NRX Pharmaceuticals (NRXP) Net Cash Flow (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Net Cash Flow for 10 consecutive years, with -$1.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 126.53% year-over-year to -$1.1 million; the TTM figure through Mar 2026 stood at $3.7 million (down 11.73% YoY), while the FY2025 annual figure was $6.4 million, up 301.97% from the prior year.
- Net Cash Flow fell to -$1.1 million in Q1 2026 per NRXP's latest filing, from $625000.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $12.6 million in Q1 2022 and bottomed at -$15.7 million in Q2 2022.
- Historically, Net Cash Flow has averaged -$1.1 million across 5 years, with a median of -$1.1 million in 2026.
- Annual changes were most pronounced in 2022 — Net Cash Flow plunged 13712.17% — and 2025, when it surged 2812.3%.
- NRX Pharmaceuticals' Net Cash Flow stood at $1.8 million in 2022, then slumped by 338.61% to -$4.3 million in 2023, then soared by 95.29% to -$203000.0 in 2024, then soared by 407.88% to $625000.0 in 2025, then slumped by 274.24% to -$1.1 million in 2026.
- Business Quant data shows NRXP's Net Cash Flow at -$1.1 million in Q1 2026, $625000.0 in Q4 2025, and $6.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | 19.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.09 Mn |
| Mar 31, 2026 | -1.09 Mn |
| Dec 31, 2025 | 625,000.00 |
| Dec 31, 2025 | 625,000.00 |
| Sep 30, 2025 | 6.84 Mn |
| Sep 30, 2025 | 6.84 Mn |
| Jun 30, 2025 | -2.64 Mn |
| Jun 30, 2025 | -2.64 Mn |
| Mar 31, 2025 | 4.11 Mn |
| Mar 31, 2025 | 4.11 Mn |
| Dec 31, 2024 | -203,000.00 |
| Dec 31, 2024 | -203,000.00 |
| Sep 30, 2024 | -252,000.00 |
| Sep 30, 2024 | -252,000.00 |
| Jun 30, 2024 | 579,000.00 |
| Jun 30, 2024 | 579,000.00 |
| Mar 31, 2024 | -3.28 Mn |
| Mar 31, 2024 | -3.28 Mn |
| Dec 31, 2023 | -4.31 Mn |
| Dec 31, 2023 | -4.31 Mn |